Evidence Explorer · MS-N222 · Nutrition support and omega-3 formulations · Appraised November 3, 2026
A small randomized trial reported improved energy and protein intake and a lean-mass signal with an EPA-containing oral supplement during platinum-taxane chemotherapy for advanced non-small-cell lung cancer. It found no response-rate or overall-survival advantage.
Evidence at a glance
Benefit signal: Positive body-composition signal; no cancer-control benefit
Certainty: Low because the trial was small and single-center
Risk context: Supplement tolerance, allergy and drug/procedure context require review
What was studied
Ninety-two analyzed patients were randomized 46:46 to diet plus an EPA-containing oral supplement or an isocaloric diet during paclitaxel plus cisplatin/carboplatin treatment.
Lean body mass changed by +1.6 ± 5 kg versus −2.0 ± 6 kg (P=0.01); energy and protein intake were higher. The abstract reported symptom improvements, but response rate and overall survival did not differ.
What this evidence cannot establish
The analyzed sample was small, the formulation and exact EPA dose were not fully verified from accessible full text, and secondary outcomes were numerous.
Body-composition and symptom findings cannot be interpreted as antitumor activity. The result does not establish that fish-oil capsules reproduce a complete oral nutrition formula.
Practical safety context
Discuss bleeding risk, fish allergy, gastrointestinal tolerance and the full supplement list with the oncology team. Product calories, protein and micronutrients—not EPA alone—may matter.
Unintentional weight loss during lung-cancer treatment warrants assessment for inadequate intake, swallowing problems, inflammation and reversible symptoms.
Questions for the care team
- What exact product, EPA dose and calorie/protein contribution would match the study?
- How will lean mass or function be assessed, rather than weight alone?
- Could the supplement worsen nausea, reflux, early satiety or treatment interactions?
Sources
- Randomized trial in advanced NSCLC (PMID 24746976)
Sources and publication status checked November 3, 2026. Abstract-level appraisal; inaccessible full text limited verification of formulation, funding and conflicts.
For education, not personal medical advice. Nutrition and supplement decisions during cancer care should be individualized with the oncology and dietetics teams.
